HOME >> BIOLOGY >> NEWS
Over the edge: New therapeutic strategy takes advantage of stressed cancer cells

A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves. Scientists have successfully exploited the oxidative stress common in cancer cells to preferentially kill malignant cells. This approach has the therapeutic advantage of selectively targeting cancer cells while exhibiting minimal toxicity in normal cells. The research is published in the September 2006 issue of the journal Cancer Cell, published by Cell Press.

Most cancer cells exhibit overproduction of reactive oxygen species (ROS), which is thought to provide favorable conditions for cancer cell growth, genetic instability, and survival. Dr. Peng Huang from the Department of Molecular Pathology at the University of Texas M.D. Anderson Cancer Center and colleagues hypothesized that increased ROS generation may also make cancer cells highly vulnerable to exogenous ROS-modulating agents that would not be toxic to normal cells with low ROS output.

The researchers examined the ability of a naturally occurring compound called -phenylethyl isothiocyanate (PEITC), which is known to modulate cellular antioxidant pathways, to push cancer cells to even higher ROS levels that result in cell death. Oncogenically transformed cells exhibited high basal ROS levels and were more sensitive to PEITC than nontransformed cells. PEITC interfered with a specific antioxidant system that the cancer cells relied on to maintain a ROS balance that was compatible with survival. Treatment with PEITC led to further ROS accumulation that caused massive death of cancer cells but no cytotoxicity in normal cells. Importantly, PEITC also significantly prolonged survival in an animal model of human cancer.

"Our study suggests that the intrinsic oxidative stress in cancer cells associated with oncogenic transformation provides a basis for developing therapeutic strategies to preferentially kill cancer cell
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
11-Sep-2006


Page: 1 2

Related biology news :

1. On the cutting edge: Carbon nanotube cutlery
2. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
3. From clinical cancer research: rethinking therapeutic cancer vaccine trials
4. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
5. New therapeutic insight into duchenne muscular dystrophy
6. Small molecule derived from Rb2/p130 could act as cancer therapeutic
7. Sphingolipids with therapeutic ends
8. New therapeutic target for Alzheimers could lead to drugs without side effects
9. VBI research offers potential route to diabetes therapeutics
10. Quiet revolution may herald new RNA therapeutics
11. Scientists discover two-component lantibiotic with therapeutic potential

Post Your Comments:
(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/24/2015)... 2015  Based on its recent analysis of the biometric ... African Biometrics Company of the Year Award. DERMALOG is the ... in Africa . It has particularly gained ... implemented one of the largest biometric mass applications in the ... Central Bank of Nigeria with its ...
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 /PRNewswire/ ... Sponsoring der Gewinner des Wettbewerbs BeHEARD von 2015 ... einen internationalen vom Rare Genomics Institute. ... Wirksamkeit von Medikamenten für die Behandlung anderer Krankheiten ... wurde, Steven Laffoon und sein Team ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... will improve efficiency of their entire waste to energy process and continue to ... Gets a Major Upgrade , Temarry’s Waste to Energy process has been operating ...
(Date:9/1/2015)... September 2, 2015 ... die Forschung und Entwicklung neuartiger Therapien für ... Darmerkrankungen und Reizdarm konzentriert, erhält vom US ... sein neues Medikament patentiert wird. Das Medikament ... bei Kindern verhindert und Entzündungen vorbeugt.   ...
(Date:9/1/2015)...  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... Global Investment Conference sponsored by H.C. Wainwright ... St. Regis Hotel in New York, NY ... Chief Executive Officer, will provide an overview of the ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Temarry Recycling’s New $100,000 Waste to Energy Renovation 2Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
Cached News: